A detailed history of Jane Street Group, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 863,764 shares of EDIT stock, worth $2.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
863,764
Previous 290,136 197.71%
Holding current value
$2.06 Million
Previous $1.35 Million 117.5%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.39 - $5.96 $1.94 Million - $3.42 Million
573,628 Added 197.71%
863,764 $2.95 Million
Q2 2024

Aug 14, 2024

BUY
$4.67 - $7.28 $584,973 - $911,907
125,262 Added 75.97%
290,136 $1.35 Million
Q1 2024

May 15, 2024

SELL
$7.03 - $11.07 $9,581 - $15,088
-1,363 Reduced 0.82%
164,874 $1.22 Million
Q4 2023

Feb 14, 2024

BUY
$6.25 - $11.11 $607,825 - $1.08 Million
97,252 Added 140.98%
166,237 $1.68 Million
Q3 2023

Nov 14, 2023

SELL
$6.92 - $9.31 $1.39 Million - $1.86 Million
-200,155 Reduced 74.37%
68,985 $538,000
Q2 2023

Aug 14, 2023

BUY
$6.36 - $11.47 $984,979 - $1.78 Million
154,871 Added 135.53%
269,140 $2.22 Million
Q1 2023

May 15, 2023

BUY
$7.03 - $11.53 $49,652 - $81,436
7,063 Added 6.59%
114,269 $828,000
Q4 2022

Feb 14, 2023

SELL
$8.32 - $13.21 $126,830 - $201,373
-15,244 Reduced 12.45%
107,206 $950,000
Q3 2022

Nov 14, 2022

SELL
$12.16 - $19.42 $79,100 - $126,327
-6,505 Reduced 5.04%
122,450 $1.5 Million
Q3 2022

Nov 14, 2022

SELL
$12.16 - $19.42 $79,100 - $126,327
-6,505 Reduced 5.04%
122,450 $1.5 Million
Q2 2022

Aug 16, 2022

BUY
$9.99 - $21.35 $688,101 - $1.47 Million
68,879 Added 114.65%
128,955 $1.53 Million
Q1 2022

May 17, 2022

SELL
$14.08 - $27.63 $2.47 Million - $4.85 Million
-175,382 Reduced 74.49%
60,076 $1.14 Million
Q4 2021

Feb 15, 2022

BUY
$26.55 - $40.57 $4.4 Million - $6.72 Million
165,759 Added 237.82%
235,458 $6.25 Million
Q3 2021

Nov 16, 2021

SELL
$39.27 - $72.94 $615,125 - $1.14 Million
-15,664 Reduced 18.35%
69,699 $2.86 Million
Q2 2021

Aug 16, 2021

SELL
$31.29 - $56.64 $5.12 Million - $9.26 Million
-163,563 Reduced 65.71%
85,363 $4.84 Million
Q1 2021

May 18, 2021

BUY
$39.71 - $90.58 $4.52 Million - $10.3 Million
113,804 Added 84.22%
248,926 $10.5 Million
Q4 2020

Feb 17, 2021

BUY
$27.07 - $84.35 $2.58 Million - $8.04 Million
95,322 Added 239.5%
135,122 $9.47 Million
Q3 2020

Nov 17, 2020

SELL
$28.06 - $37.16 $1.38 Million - $1.83 Million
-49,307 Reduced 55.33%
39,800 $1.12 Million
Q2 2020

Aug 17, 2020

BUY
$18.5 - $34.34 $1.27 Million - $2.35 Million
68,463 Added 331.64%
89,107 $2.64 Million
Q4 2019

Feb 14, 2020

BUY
$19.49 - $32.63 $402,351 - $673,613
20,644 New
20,644 $611,000
Q2 2019

Aug 15, 2019

SELL
$20.48 - $27.76 $1.13 Million - $1.53 Million
-54,990 Closed
0 $0
Q1 2019

May 16, 2019

BUY
$19.43 - $26.41 $280,569 - $381,360
14,440 Added 35.61%
54,990 $1.34 Million
Q4 2018

Feb 15, 2019

BUY
$18.19 - $31.79 $342,572 - $598,701
18,833 Added 86.72%
40,550 $923,000
Q1 2018

May 15, 2018

BUY
$29.84 - $44.08 $648,035 - $957,285
21,717 New
21,717 $720,000
Q4 2017

Feb 15, 2018

SELL
$21.89 - $31.34 $413,086 - $591,417
-18,871 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$15.81 - $24.01 $298,350 - $453,092
18,871
18,871 $453,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $164M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.